Evidence map›Paper›PMID 21969811›Full record

ArticleNeoplasia (New York, N.Y.)2011

G-DOC: a systems medicine platform for personalized oncology.

Subha Madhavan, Yuriy Gusev, Michael Harris, David M Tanenbaum, Robinder Gauba, Krithika Bhuvaneshwar, Andrew Shinohara, Kevin Rosso, Lavinia A Carabet, Lei Song and 6 more

Abstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. PMBC: a manually curated database for prognostic markers of breast cancer.Database : the journal of biological databases and curation · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Subha MadhavanLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA. sm696@georgetown.edu
Yuriy Gusev
Michael Harris
David M Tanenbaum
Robinder Gauba
Krithika Bhuvaneshwar
Andrew Shinohara
Kevin Rosso
Lavinia A Carabet
Lei Song
Rebecca B Riggins
Sivanesan Dakshanamurthy
Yue Wang
Stephen W Byers
Robert Clarke
Louis M Weiner

Funding

Novel Targets in Endocrine ResponsivenessU54CA149147 · NCI · GEORGETOWN UNIVERSITY · PI CLARKE, ROBERT R. · 2010 to 2014
$6.9M
TARGETED IMMUNOTHERAPY USING BISPECIFIC ANTIBODIESR01CA050633 · NCI · GEORGETOWN UNIVERSITY · PI WEINER, LOUIS M. · 1989 to 2018
$6.5M
MACE2K - Molecular And Clinical Extraction: A Natural Language Processing Tool for Personalized MedicineU01HG008390 · NHGRI · GEORGETOWN UNIVERSITY · PI MADHAVAN, SUBHA · 2015 to 2017
$1.5M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS R01 CA050633NCI NIH HHS U54 CA149147NCI NIH HHS U54-CA149147NHGRI NIH HHS U01 HG008390
6 · The paper itself

Abstract

Currently, cancer therapy remains limited by a "one-size-fits-all" approach, whereby treatment decisions are based mainly on the clinical stage of disease, yet fail to reference the individual's underlying biology and its role driving malignancy. Identifying better personalized therapies for cancer treatment is hindered by the lack of high-quality "omics" data of sufficient size to produce meaningful results and the ability to integrate biomedical data from disparate technologies. Resolving these issues will help translation of therapies from research to clinic by helping clinicians develop patient-specific treatments based on the unique signatures of patient's tumor. Here we describe the Georgetown Database of Cancer (G-DOC), a Web platform that enables basic and clinical research by integrating patient characteristics and clinical outcome data with a variety of high-throughput research data in a unified environment. While several rich data repositories for high-dimensional research data exist in the public domain, most focus on a single-data type and do not support integration across multiple technologies. Currently, G-DOC contains data from more than 2500 breast cancer patients and 800 gastrointestinal cancer patients, G-DOC includes a broad collection of bioinformatics and systems biology tools for analysis and visualization of four major "omics" types: DNA, mRNA, microRNA, and metabolites. We believe that G-DOC will help facilitate systems medicine by providing identification of trends and patterns in integrated data sets and hence facilitate the use of better targeted therapies for cancer. A set of representative usage scenarios is provided to highlight the technical capabilities of this resource.

Indexed as

Breast NeoplasmsDatabases as TopicGastrointestinal NeoplasmsPrecision MedicineComputational BiologyDecision Making, Computer-AssistedFemaleGenomicsHigh-Throughput Screening AssaysHumansInternetMetabolomicsSystems BiologyTranscriptomeTreatment Outcome

Identifiers

PMID21969811
PMCPMC3182270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.